Author

S. Nag

Observed names: S Nag, S. M. Nag

Institution: Sahyadri Hospital

Observed institutions: Loyola University Chicago, Clínica Las Condes, Fundación Instituto Valenciano de Oncología, Addington Hospital, Inlaks & Budhrani Hospital, Instituto Nacional de Cancerología, Sahyadri Hospital

ORCID: 0009-0004-8377-5692

Observed ORCID: 0009-0004-8377-5692

OpenAlex ID: A5111331772

Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva

2004 · K. S. Albain, S. Nag, et al. · Journal of Clinical Oncology · 161

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

2008 · P K Julka, R T Chacko, et al. · British Journal of Cancer · 46

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

2024 · K.H. Park, S. Loibl, et al. · ESMO Open · 31

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer

2025 · S. Nag, I. Ray Coquard, et al. · ESMO Open · 11

372P Prevalence of BRCA1 and BRCA2 mutation among Indian breast cancer patients: A multicentre cross-sectional study

2023 · S. Nag, D. Arya, et al. · Annals of Oncology · 2

A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate safety and immunogenicity of Dr. Reddy’s Trastuzumab (DRL_TZ) in Patients with HER2-Positive Advanced Breast Cancer

2024 · S. Nag, C. Deshmukh, et al. · European Journal of Cancer · 1

Phase III study of gemcitabine (G) plus paclitaxel (T) versus T in patients with metastatic breast cancer (MBC) – Post-study chemotherapy (PSC) trend analysis

2008 · A. Llombart, S. Nag, et al. · European Journal of Cancer Supplements · 1

A Prospective, Single arm, Multicentre, Post-marketing Study (Phase IV) to evaluate effectiveness of Dr. Reddy’s Trastuzumab (DRL_TZ) in Patients with HER2-Positive Advanced Breast Cancer

2024 · S. Nag, C. Deshmukh, et al. · European Journal of Cancer

Efficacy and safety of gefitinib as an option in the first- or second-line treatment of Indian patients with advanced NSCLC with poor performance status.

2010 · S. M. Nag, C. Koppiker, et al. · Journal of Clinical Oncology

Works count: 9

Citation count: 253

H-index: 4

I10-index: 4